title: Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease.
abstract: Atrial fibrillation (AF) is about three-times more prevalent in patients with chronic kidney disease and the prevalence of AF increases with the degree of renal impairment. Clinical studies have shown increased risk of stroke, bleeding and death in patients with chronic kidney disease and AF. Despite, this increased risk, anticoagulation is underutilized due to increased bleeding risk in this population. Recently direct thrombin inhibitors and factor Xa inhibitors have been shown to be more efficacious in stroke prevention with reduced bleeding than warfarin. As the usage of these novel anticoagulants increases it is important to understand the data available in regard to these high risk patients.
authors.affiliation: Department of Medicine, University of Wisconsin School of Medicine, 1685 Highland Avenue, Madison, WI-53593, USA.
authors.forename: Mohit K
authors.initials: MK
authors.lastname: Turagam
authors.forename: Naga S
authors.initials: NS
authors.lastname: Addepally
authors.forename: Poonam
authors.initials: P
authors.lastname: Velagapudi
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D015195:Drug Design; D065427:Factor Xa Inhibitors; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D065427:Factor Xa Inhibitors